

ASX Release**Board change**

Brisbane, Australia 9 June 2022: Oventus Medical Ltd (ASX: OVN) (“**Oventus**” or “**Company**”) today announces the resignation of Dr. Chris Hart, which took effect on 8 June 2022. The Board has commenced a search for a new Australian resident director to ensure its compliance with the *Corporations Act 2001* (Cth) and will keep the market updated.

“On behalf of the Board, I want to thank Chris for his contribution to Oventus. He invented the technology and led Oventus through its early stages. He is leaving the Board to return to his clinical practice.”

Until this process is complete, the Board considers it prudent to place Oventus into voluntary suspension, such that its shares will be suspended from trading, until a new Australian resident Director has been appointed.

—ENDS—

Authorised for release by the Oventus Medical Ltd Board of Directors.

For further information, please visit our website at www.o2vent.com or contact the individuals outlined below.

Investors:

John Cox, CEO: M: +1 (949) 444-8532 or investors@oventus.com.au

Media:

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

About Oventus – see more at www.o2vent.com

Oventus Medical’s mission is to be a global leader in the management of sleep-disordered breathing, by providing a seamless patient journey and innovative oral appliance therapies. Oventus’ Obstructive Sleep Apnea (OSA) treatment, called the O2Vent, has been demonstrated to be more effective and more desirable than other treatment options, offering hope for discreet, comfortable and effective relief to millions of people suffering from OSA. Based in Brisbane, Australia and Irvine, California, the company has extensive clinical data demonstrating that its platform, with integrated airway support, has the potential to be accepted as a preferred first-line therapy for patients with mild to moderate sleep apnea.

In order to become the first choice for patients and clinicians alike, Oventus also makes the process for entering OSA treatment efficient, engaging and convenient. Oventus and its clinical partners have developed a virtual consultation and fitting process that enables patients to receive their custom-fit device and initiate therapy from the comfort of their home, all while maintaining the highest standards of service and patient

O2Vent®



care. By developing a complete solution, from best-in-class technology to outstanding care, Oventus has raised the bar for Sleep Apnea treatments in a rapidly-growing US\$31B addressable market.